Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
Recent studies have highlighted the successes of chimeric antigen receptor-modified T- (CART-) cell-based therapy for B-cell malignancies, and early phase clinical trials have been launched in recent years. The few published clinical studies of CART cells in solid tumors have addressed safety and fe...
Saved in:
Main Authors: | Yelei Guo, Yao Wang, Weidong Han |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2016/3850839 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
by: Ugo Testa, et al.
Published: (2024-10-01) -
Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells
by: Pengju Wang, et al.
Published: (2025-01-01) -
Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01) -
Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy
by: Charles J. Milrod, et al.
Published: (2025-02-01) -
Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
by: Chengcheng Zhang, et al.
Published: (2023-05-01)